Showing results (661-670 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|August 4, 2019
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trialJeremie Calais, Francesco Ceci, Matthias Eiber, et al.
The Lancet. Oncology|April 22, 2008
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological studySimon M Collin, Richard M Martin, Chris Metcalfe, et al.
The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.
The Lancet. Oncology|May 31, 2008
Role of the cerebellum in the neurocognitive sequelae of treatment of tumours of the posterior fossa: an updateDavid Cantelmi, Tom A Schweizer, Michael D Cusimano
The Lancet. Oncology|May 31, 2008
Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitionsGauri R Varadhachary, Martin N Raber, Aurelio Matamoros, et al.
The Lancet. Oncology|March 14, 2014
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational studyMasaaki Yamamoto, Toru Serizawa, Takashi Shuto, et al.
The Lancet. Oncology|April 18, 2014
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 studyBertrand Tombal, Michael Borre, Per Rathenborg, et al.
The Lancet. Oncology|April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyPippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
The Lancet. Oncology|January 5, 2017
Follow-up care of cancer survivors: challenges and solutionsLinda A Jacobs, Lawrence N Shulman
The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.
Pageof 336